# Mangoceuticals, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Mangoceuticals, Inc).

## Overview

Mangoceuticals, Inc. operates a telemedicine and e-commerce-style healthcare platform focused on men’s wellness. Through MangoRx.com, it connects consumers with licensed healthcare professionals and markets prescription-based products for erectile dysfunction, hair loss, hormone support, and weight management, including compounded products and the FDA-approved PRIME testosterone therapy offering.

## Products & services

• Mango ED compounded erectile dysfunction treatment
• Grow hair-loss products
• Mojo hormone balance / therapy products
• Slim weight-management products
• PRIME by MangoRx, powered by Kyzatrex®
• Telehealth consultations via MangoRx.com

- **Compounded men’s wellness products** (70%) — Custom-compounded prescription products for ED, hair loss, hormone support, and weight loss.
- **FDA-approved prescription therapy** (20%) — PRIME by MangoRx, powered by Kyzatrex®, an oral testosterone replacement therapy.
- **Telemedicine platform services** (10%) — Online access to licensed healthcare professionals and prescription fulfillment workflow.

- Mango ED compounded erectile dysfunction treatment
- Grow hair-loss products
- Mojo hormone balance / therapy products
- Slim weight-management products
- PRIME by MangoRx, powered by Kyzatrex®
- Telehealth consultations via MangoRx.com

## Customers

The company sells primarily to adult men seeking discreet, online access to prescription wellness treatments. Its customers are typically patients looking for convenience, privacy, and physician-directed treatment for conditions such as erectile dysfunction, hair loss, low testosterone, and weight management. The platform also depends on prescribers and pharmacy fulfillment partners to convert demand into completed orders.

- **Men seeking ED treatment** (primary) — Buy Mango ED products for discreet, prescription-based erectile dysfunction care.
- **Men with hair-loss concerns** (secondary) — Buy Grow-branded products to address hair-loss treatment needs through telemedicine.
- **Men with low testosterone or hormone issues** (primary) — Buy Mojo products or PRIME for testosterone-related therapy and symptom management.
- **Weight-management patients** (secondary) — Buy Slim products for prescription-based weight-loss support.
- **Telehealth users** (secondary) — Use the platform to connect with licensed healthcare professionals and obtain prescriptions.

- Adult men seeking discreet treatment for ED and related conditions
- Patients wanting online access instead of in-person clinic visits
- Consumers seeking hair-loss, testosterone, or weight-loss therapies
- Physicians who prescribe compounded or branded therapies
- Patients who value convenience, privacy, and home delivery

## Geography

Mangoceuticals is headquartered in Dallas, Texas and appears to operate primarily in the United States. Its business is tied to U.S. telemedicine, pharmacy fulfillment, and FDA/regulatory requirements, so domestic healthcare rules are a central operating constraint. The company has not disclosed a meaningful country-by-country revenue split in the provided excerpts.

- Headquartered in Dallas, Texas
- Primary operating market is the United States
- U.S. telemedicine rules shape product access and marketing
- Pharmacy fulfillment is tied to domestic prescription workflows
- No country-level revenue disclosure was provided

## Strategy

Management is focused on aggressive customer acquisition through marketing, platform enhancements, and expansion of its men’s wellness product set. The company also wants to grow organically and through acquisitions in technology, health, and wellness, but execution depends on continued access to capital. Its strategy is built around scaling a digital healthcare brand while broadening the product mix and fulfillment capabilities.

- **Customer acquisition through marketing** (short-term) — The model depends on generating online demand for prescription products.
- **Platform and product expansion** (medium-term) — Broader offerings can increase repeat usage and cross-sell across men’s wellness categories.
- **Acquisition-led growth** (medium-term) — Acquisitions could add products, technology, or distribution, but require funding and integration.

- Increase marketing to attract new customers for pharmaceutical products
- Enhance the telemedicine platform and customer experience
- Expand men’s health and wellness product offerings
- Pursue acquisitions in technology, health, and wellness
- Secure financing to support growth and operations

## Risks

The company is highly exposed to FDA, telemedicine, and compounding-pharmacy regulation because its products are prescription-based and sold online. It also faces financing risk, since operations and growth plans depend on external capital and management has indicated that future funding could be dilutive. Product concentration, related-party fulfillment, and the replicability of compounded formulas add competitive and execution risk.

- **Regulatory delay or restriction** [high] — The business sells prescription products online and depends on FDA and state healthcare rules.
- **Capital shortage and dilution** [high] — The company states it may need additional debt or equity financing to fund operations and growth.
- **Related-party fulfillment dependence** [medium] — All compounded products and Prime orders are fulfilled by Epiq Scripts, a related-party pharmacy.
- **Competitive replication of products** [medium] — The company notes its compounded formulas are publicly disclosed and can be replicated.

- FDA and telemedicine regulation can delay launches or restrict marketing
- Government shutdowns may slow approvals, inspections, and SEC filings
- Funding needs are ongoing and future capital raises may be dilutive
- Related-party pharmacy dependence creates concentration and governance risk
- Compounded formulas can be replicated by competitors
- Aggressive growth spending may outpace customer demand

## Accounting

Investors should watch revenue recognition around prescription fulfillment, marketing arrangements, and any bundled service/product offerings, since timing can affect quarterly results. The company also highlights estimates for stock-based compensation, intangible assets, goodwill, doubtful accounts, sales returns, and litigation, all of which can materially move reported earnings. Because it relies on equity-based consideration and related-party arrangements, non-cash expenses and valuation judgments are especially important.

- **Revenue recognition for telemedicine and prescription fulfillment** — Quarterly revenue and deferred revenue balances
- **Stock-based compensation** — Operating expenses and earnings per share
- **Goodwill and intangible asset impairment** — Potential non-cash write-downs
- **Related-party transactions and licensing agreements** — Expense recognition, liabilities, and comparability

- Revenue timing may depend on prescription fulfillment and service delivery
- Stock-based compensation can materially affect reported expenses
- Goodwill and intangible asset impairment are key judgment areas
- Allowance for doubtful accounts and sales returns affect net revenue
- Related-party and licensing arrangements may require valuation estimates
- Litigation and contingencies can create accrual volatility

---

*Last updated: 2026-09-24T12:34:15.273986+00:00*